Phase 2 MG Clinical Trials
11 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 2
G-CSF After Chemo-radiation in Patients With Glioblastoma
Glioblastoma (GBM)MGMT-Methylated GlioblastomaNewly Diagnosed Glioblastoma Multiforme
Massachusetts General Hospital60 enrolled1 locationNCT06649851
Recruiting
Phase 2
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled9 locationsNCT07284420
Recruiting
Phase 2
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled20 locationsNCT06140524
Recruiting
Phase 1Phase 2
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
MGMT-Unmethylated GlioblastomaHigh Grade GliomaMGMT-Methylated Glioblastoma
University of California, San Francisco70 enrolled5 locationsNCT06504381
Recruiting
Phase 2
The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy
Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy
University of Alabama at Birmingham12 enrolled5 locationsNCT06599697
Recruiting
Phase 2
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Glioblastoma, IDH-wildtypeMGMT-Unmethylated Glioblastoma
Northwestern University39 enrolled2 locationsNCT05879250
Recruiting
Phase 2
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Brain CancerGlioblastomaGlioblastoma Multiforme+4 more
Baptist Health South Florida190 enrolled1 locationNCT06991101
Recruiting
Phase 1Phase 2
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Newly Diagnosed MGMT Unmethylated Glioblastoma
Darell Bigner50 enrolled1 locationNCT05734560
Recruiting
Phase 2
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
Advanced GlioblastomaMetastatic Melanoma in the Central Nervous SystemMGMT-Unmethylated Glioblastoma
Sheba Medical Center33 enrolled1 locationNCT05909618
Recruiting
Phase 1Phase 2
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Myasthenia GravisGeneralized MyastheniaAChR Myasthenia Gravis+1 more
COUR Pharmaceutical Development Company, Inc.54 enrolled17 locationsNCT06106672